Cerdulatinib Completed Phase 2 Trials for Vitiligo Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04103060Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo